Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen) by unknown
HUMAN  T  CELL  ACTIVATION 
II. A  New Activation Pathway Used by a  Major T  Cell Population Via a 
Disulfide-bonded Dimer of a  44 Kilodalton Polypeptide (9.3 Antigen) 
BY TOSHIRO HARA,  SHU MAN FU,  AND JOHN A. HANSEN* 
From the Cancer Research Program, Oklahoma Medical Research Foundation,  Oklahoma City, 
Oklahoma  73104, and the *Histocompatibility Laboratory, Puget Sound Blood Center and 
Fred Hutchinson Cancer Research Center, Seattle,  Washington  98104 
Considerable progress has been made in the delineation of human functional 
T  cell subsets and in the identification of T  cell-specific and -associated antigens 
(reviewed in  1 and 2).  Some of these antigens are closely involved in human T 
cell activation and proliferation.  The importance of the T3/Ti  (Ti,  putative T 
cell  receptor) 1 complex  in  antigen-specific  T  cell  activation  has  recently  been 
reviewed  (3,  4).  Although  this  is  a  major  activation  pathway,  an  alternative 
antigen-independent  pathway involving the T11 antigen,  the sheep erythrocyte 
receptor, has been proposed (5, 6). Two unique anti-T11  monoclonal antibodies 
(mAb)  in  combination  were  shown  to  activate  T  cells by Ca 2+  influx,  and  to 
induce  T  cells  to  proliferate.  This  pathway  was  shown  to  be  related  to  the 
T3/Ti  complex in that modulation of the T3/Ti complex inhibited the effects 
by these two mAb. 
Recently,  we demonstrated  that  anti-T3  mAb,  in  collaboration  with  tumor 
promoter  12-0-tetradecanoyl phorbol-13-acetate (TPA), induced human T  cells 
to express interleukin-2  (IL-2) receptors, to secrete IL-2, and to proliferate (7). 
This  process was  independent  of monocytes.  Herein,  other  anti-T  cell  mAb 
were screened  for  their  effects on  T  cell  activation  in  this  system,  mAb  9.3, 
reactive with a disulfide-bonded dimer of a  44 kilodalton (kD) polypeptide on a 
major T  cell population, was found to induce T  cell activation and proliferation 
in  collaboration  with  TPA,  in  a  manner  similar  to  that  of the  anti-T3  mAb. 
Modulation  of the T3/Ti  complex did not inhibit  the effects induced by mAb 
9.3 and TPA. Thus, antigen  9.3 is involved in a  novel activation pathway used 
by a major T  cell population. 
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Materials and  Methods 
Monoclonal Antibodies.  Purified  mAb 9.3,  9.6  (Tll),  3.5  (T12),  10.2  (Leu-1),  17.2 
(T4), and  10.1  (T8) were obtained from ascitic fluids as described previously (8).  The 
assignment of specificities to these antibodies were done by their cellular reactivities and 
by the molecular weights of the reactive antigens,  mAb TE (T11) and  235  (T3) were 
generated in our laboratory as described (7). Anti-putative T  cell receptor (anti-Ti) mAb 
$511  and C37 were generous gifts from Dr. R. Bigler (The Rockefeller University, NY) 
and Drs. Y. Buskkin and C. Y. Wang (Sloan-Kettering Cancer Center, NY), respectively. 
Biotinylation of Purified mAb AT-1.  mAb AT-l, directed against the IL-2 receptor, was 
produced  as  described  previously (9).  Biotinylation  of purified  AT-1  was carried  out 
according to a standard method. 0.5 ml of AT-1 (1  mg/ml) in 0.2 M Tris HCI, pH 8.1, 
was  mixed  quickly  with  0.1  ml  of  3.4  mg/mi  of biotin  N-hydroxysuccinimide  ester 
(Calbiochem-Behring Corp.,  San  Diego,  CA) solution  and stirred  for 30  min at room 
temperature.  The biotinylated AT-1  was extensively dialyzed against  PBS  (phosphate- 
buffered saline). 
Cell Preparation.  Peripheral mononuclear cells (PMC) were isolated from buffy-coats 
from normal donors or peripheral blood, using Ficoll-Hypaque density gradient centrif- 
ugation.  To  isolate  monocyte-free T  cells,  PMC  were  further  separated  by  Percoll 
continuous  gradient  centrifugation,  followed  by carbonyl  iron  treatment,  nylon  wool 
column, and plastic adherence (10-12). Monocyte-free T cells were also obtained by sheep 
red blood cell (SRBC) rosetting (13), carbonyl iron treatment, nylon wool column, and 
plastic adherence. These T  cell preparations contained <0.1% monocytes, by nonspecific 
esterase staining. SRBC rosetting separation had no effect on the results, although TI 1 
antigen was found to be an alternative pathway of T  cell activation (5). 
Cells were suspended in complete medium consisting of RPMI 1640 (Gibco Laborato- 
ries, Grand Island, NY) supplemented with  10% heat-inactivated fetal calf serum (FCS) 
(HyClone Laboratories, Logan, UT), 2 mM L-glutamine, and 50 #g/ml gentamicin (Gibco 
Laboratories). In some experiments,  10%  heat-inactivated human  AB serum (HS) was 
used instead of FCS. 
Immunofluorescence Studies.  Cells were stained  with mAb at 4°C  for 30  min.  After 
extensive washing,  the  cells  were further  incubated  with  FITC-conjugated  goat anti- 
mouse F(ab')2 at 4°C for 30 min. For the study of IL-2 receptor expression, biotinylated 
AT-1  was used as the first ligand, and FITC-conjugated avidin (Becton Dickinson and 
Co., Mountain View, CA) was used as the second ligand antibody. After wash, the cells 
were analyzed with a Coulter Epics V flow cytometer (Coulter Electronics Inc., Hialeah, 
FL). Integrated fluorescence of the gated population was measured, and 10,000 cells were 
analyzed. 
Proliferation Assays.  PMC or monocyte-depleted T  cells (2  ×  I 05 ceils)  in  200 #1 of 
complete medium were incubated in triplicate in flat-bottomed, 96-well plates at 37°C 
for 3 d  in a  5% CO2 atmosphere. During the last 8 h, cells were pulsed with 0.4 #Ci of 
[SH]thymidine (sp act 75 Ci/mmol; Amersham Corp., Arlington Heights, IL), and incor- 
porated radioactivity was determined as described (14).  For proliferation assays, TPA 
(Sigma Chemical  Co.,  St.  Louis,  MO),  recombinant  IL-2, and  purified  IL-2 and  IL-1 
(Genzyme, Boston, MA) were used. 
Modulation Studies.  PMC (106 cells/ml) or cells of the HPB-ALL leukemic line (2.5 × 
105 cells/ml) in complete medium were incubated with a saturating dose of mAb for 18 h 
at 37 °C. Cells were washed three times, then stained as described above. 
IL-2 Activity Assay.  4  ×  l0 s murine  IL-2-dependent HT-2 cells  (a gift from Dr.  K. 
Himeno of the Oklahoma Medical Research Foundation)  in  100  #1 complete medium, 
containing  2.5  ×  10 -5  M  2-mercaptoethanol  were  incubated  with  100  #i  of culture 
supernatants of various dilutions, in triplicate, at 37°C for 24 h. Then, 0.4 #Ci of [3H]- 
thymidine was added, and incubation was continued for another 4 h. The incorporated 
radioactivity was assayed as described above. 
IL-2  Production.  T  cells  (106  cells/ml)  in  complete  medium  were  cultured  in  the 
presence of various activators for  12  h.  Supernatants were collected by centrifugation, 
filtered, and assayed for IL-2 activity as described above. HARA ET  AL.  1515 
lodination,  Immunoprecipitation and Autoradiography.  T  lymphocytes  (2 x  107) were 
labeled with 12~I (sp act 15.8 mCi/#g of iodine,  Amersham Corp.) by the lactoperoxidase 
technique (7). Immunoprecipitation and autoradiography were performed as described 
(7). For electrophoresis in nonreduced condition, cells were preincubated in PBS contain- 
ing 10 mM iodoacetamide before lysis, and then lysed in lysis buffer containing  100 mM 
iodoacetamide. 
Results 
9.3 and T3/Ti are Distinct Molecules.  mAb 9.3 has been shown (15) to be an 
IgG2a cytotoxic for 50-80% of the peripheral blood T  cells. By immunofluores- 
cence, it stained 60-80% of the isolated T  cells. Initially, mAb 9.3 was found to 
precipitate  a  single  polypeptide of 44  kD  from Jurkat,  a  T  leukemia  cell  line 
(15).  In order to ascertain  the molecular weight of the 9.3 antigen,  peripheral 
blood T  cells were  125I-]abeled  by lactoperoxidase,  and  immunoprecipitates  of 
mAb 9.3  were analyzed by sodium dodecyl sulfate-polyacrylamide gel electro- 
phoresis (SDS-PAGE) under both reduced and nonreduced conditions. As shown 
in  Fig.  1,  mAb  9.3  precipitated  an  88  kD  polypeptide  under  nonreduced 
conditions, which was reduced to a 44 kD polypeptide. 
The  relationships  among  9.3,  T3/Ti,  and  T11  antigens  were  investigated. 
FIGURE  1.  Immunoprecipitation of 9.3 antigen from t251-T lymphocytes. The precipitates 
were analyzed by SDS-PAGE (10% and 8% polyacrylamide) under reducing (R) and nonre- 
ducing (NR) conditions, respectively. Control immunoprecipitates without mAb 9.3 showed 
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mAb  9.3  induced  redistribution  of its  reactive  antigen,  but  modulation  was 
partial.  Modulation of the T3 complex from peripheral blood T  cells by anti-T3 
mAb 235  did not reduce the  staining  intensity by mAb  9.3.  Similarly,  partial 
modulation  of the  T11  antigen  by anti-T11  mAb  TE  had  no  effect on  the 
staining by mAb 9.3. 
To  define  the  relationship  between  9.3  and  T3/Ti  further,  comodulation 
experiments were carried out using HPB-ALL, a T  leukemia cell line, and mAb 
C37, which identifies the Ti molecule clonotypically on HPB-ALL. As shown in 
Fig.  2,  modulation  of the  T3  antigen  with  anti-T3  mAb  (235)  reduced  the 
staining  by anti-T3  mAb and anti-Ti  mAb C37  markedly.  Despite this  almost 
complete modulation of the T3/Ti complex, staining for 9.3 was not changed. 
As a control, anti-Leu-1  mAb was included.  Similar results were obtained when 
the T3/Ti complex was modulated with anti-Ti mAb C37 (Fig. 2 C). In another 
system  involving  T3 + human  leukemic  S  cells,  mAb  S-511  was  shown  to  be 
clonotypic (16). After modulation of the T3 complex by mAb 235, mAb S-511 
was no longer reactive with leukemic S cells, mAb 9.3 staining intensity was not 
reduced  by  this  anti-T3  mAb  treatment.  Attempts  to  modulate  the  T3/Ti 
complex by mAb S-511 were not successful. 
mAb 9.3 Induced T Cell Proliferation in the Presence  of TPA.  mAb 9.3 was not 
mitogenic either for PMC or for isolated T  cells. In the presence of TPA, mAb 
9.3  was  strongly  mitogenic  for  T  cells  that  were  contaminated  with  <0.1% 
monocytes (Table I), as well as for PMC (data not shown). The mitogenicity of 
mAb 9.3 at 1 pg/ml was dependent on the dose of TPA, and its mitogenic effect 
was apparent  even in  the presence of 0.3  ng/ml  of TPA.  Other  mAb, such as 
anti-T11,  -T12,  -Leu-1, -T4, and -T8  were not mitogenic in this system,  mAb 
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FIGURE 2.  Comodulation studies between 9.3 antigen and T3/Ti complex. Modulation of 
the T3/Ti complex did not affect the 9.3 antigen. HPB-ALL cells were incubated with media 
(A),  a saturating dose of anti-T3 mAb 235  (B),  or anti-Ti mAb C37  (C) at 37°C for 18  h. 
Cells were washed, stained, and analyzed with a flow cytometer as described in Materials and 
Methods. HARA  ET  AL.  1517 
TABLE  I 
T  Cell Proliferation in Presence of Anti -T Cell mAb and Various 
Concentrations of TPA 
Antibody (1 ug/ml) 
[3H]Thymidine uptake at TPA concentrations 
(ng/ml) of: 
0  0.3  0.6  1.0 
cpm 
9.3  208  7,720  60,091  64,233 
T3 (235)  188  16,090  66,865  66,340 
T11 (TE)  255  538  727  1,189 
TI2 (3.5)  150  988  1,548  1,945 
Leu-1 (10.2)  235  916  2,067  3,044 
T4 (17.2)  175  683  1,253  1,603 
T8 (10.1)  214  890  1,275  2,621 
Medium  194  540  1,178  2,132 
Monocyte-depleted T cells (2 x  10  5) were incubated with 1 #g/ml of mAb 
in the presence of various concentrations of TPA. [SH]Thymidine  uptake 
was measured after 3 d. The standard deviations of each mean value were 
within 15%. 
TABLE II 
T Cell Proliferation Induced by Various Concentrations ofmAb T4 or 
9.3 in Presence of TPA 
mAb 
[SH]Thymidine uptakeatantibodyconcentrations 
(ng/ml) o~ 
0  1  10  100  1,000 
cpm 
T4 (17.2)  1,225  1,007  985  1,022  1,199 
9.3  1,249  3,124  15,511  47,340  66,009 
Monocyte-depleted T  cells (2 ×  10  5) were incubated in the presence of 
various concentrations of mAb T4 or 9.3, and TPA (0.6 ng/ml). [SH]- 
Thymidine  incorporations  were determined  after  3  d.  The  standard 
deviations of each mean value were within l 5%. 
235, an anti-T3 mAb of IgM isotype was mitogenic in the presence of TPA, and 
it was included for comparison, mAb 9.3 induced a proliferative response just as 
vigorous as anti-T3 mAb. Two other experiments showed similar results. 
mAb  9.3  was  found  to  be  mitogenic,  in  a  dose-dependent  manner,  in  the 
presence of TPA (Table II). In the presence of 0.6 ng/ml of TPA, as little as  1 
ng/ml of mAb 9.3 induced a  threefold increase in [~H]thymidine uptake.  In the 
presence  of  1,000  ng/ml  of mAb  9.3,  66,009  cpm  was  detected.  An  anti-T4 
(17.2)  mAb, reactive to the helper T  cells,  was included as a  control antibody. 
This antibody had no T  cell mitogenic effect in combination with TPA. 
The mitogenic effect of mAb 9.3 in the presence of TPA was studied with T 
cells isolated without the SRBC rosetting procedure. As shown in Table III, the 
SRBC  rosetting  procedure  had  a  marginal  effect  on  the  mitogenesis  in  this 
system. In two other experiments,  not shown here,  no difference was detected 
when the two T  cell isolation procedures were compared. The effect of FCS in 
this system was also studied.  With lower concentrations of TPA (<1.0  ng/ml), 1518  ACTIVATION  OF  HUMAN  T  CELLS  BY  MONOCLONAL  ANTIBODY  9.3 
TABLE  III 
Effects of SRBC Rosetting and FCS on mAb 9.3-induced Mitogenesis 
Exp. 
[3H]Thymidine uptake at TPA concentrations 
Serum  mAb  (ng/mt) of: 
0  0.3  0.6  1.0 
A 
B 
cpm 
FCS  Medium  325  640  1,375  2,538 
9.3  301  9,996  57,247  59,996 
HS  Medium  262  393  949  1,589 
9.3  293  1,124  11,995  62,006 
FCS  Medium  276  329  968  1,533 
9.3  252  5,322  42,246  40,168 
HS  Medium  316  304  907  1,499 
9.3  386  1,064  12,385  58,690 
In exp. A, T  cells were separated by SRBC rosetting, carbonyl iron treatment, nylon wool column, 
and plastic adherence. In exp. B, T cells were separated by Percoll continuous gradient centrifugation, 
carbonyl iron treatment, nylon wool column, and plastic adherence. Monocyte-depleted T  cells (2 x 
10 ~) were incubated with or without 1 #g/ml of mAb 9.3 in the presence of various concentrations 
of TPA in complete media containing either FCS or HS. [3H]Thymidine uptake was measured after 
3 d. The standard deviations of each mean value were within 15%. 
TABLE  IV 
Effect of Various Concentrations of lL-2 or IL-1 on T Cell 
Proliferation With or Without mAb 9.3 
IL-2 
[3H]Thymidine incorporation 
Lymphokine  mAb 9.3 
Medium  (1 ug/ml) 
U/ml  cpm 
0  118  82 
125  158  171 
250  297  287 
500  511  482 
IL-1  0  650  788 
1.25  685  670 
2.5  496  590 
5.0  543  454 
10.0  670  644 
T  cells  (2  ×  10 s)  were  cultured  for  3  d  in  the  presence  of various 
concentrations of IL-1 or 1L-2 with or without 1 #g/ml of mAb 9.3. [SH]- 
Thymidine incorporation was  determined as described in Materials and 
Methods. The standard deviations of each values were within  15%. IL-2 
and IL-1 activities were confirmed using an I L-2-dependent cell line (HT- 
2), and mouse thymocytes, respectively. 
mAb  9.3  was more  mitogenic  in  FCS  than  in  HS.  However,  at  1.0  ng/ml  TPA, 
mAb  9.3  was equally mitogenic  in  both  culture  media. 
IL-I  and IL-2 Did Not Collaborate with mAb 9.3.  Addition  of IL-1  or  IL-2  to 
a  monocyte-depleted  T  cell culture  in  the presence  of  1  #g/ml  of mAb  9.3  did 
not  induce  T  cell proliferation  (Table  IV).  In  the  case  of IL-2,  as  much  as  500 HARA  ET  AL.  1519 
U/ml was added to the culture without effect. No attempts were made to see if 
these interleukins were effective in collaboration with mAb 9.3 to induce T  cell 
proliferation  in  the  presence  of monocytes.  Both  IL-1  and  IL-2  preparations 
were  shown  to  be  active  as  potent  stimulators  of  DNA  synthesis  of  mouse 
thymocytes in the presence of phytohemagglutinin,  and in IL-2-dependent HT- 
2 cells, respectively. 
T  Cell  Proliferation  Induced  by  mAb  9.3 Plus  TPA  Was  Associated  with  IL-2 
Receptor Expression and 1L-2 Production.  mAb 9.3-induced  T  cell proliferation 
in the presence of TPA  was associated with  IL-2 receptor expression and  IL-2 
production.  In  the  case  of  IL-2  receptor  expression,  biotinylated  anti-IL-2 
receptor mAb (AT-l) and  avidin-conjugated  fluorescein  isothiocyanate  (FITC) 
were used. As shown in Fig. 3, mAb 9.3 alone did not induce any increase in IL- 
2  receptor  expression,  mAb  9.3  and  TPA  markedly increased  IL-2  receptor- 
positive  cells.  By  60  h,  ~84%  of  the  cells  were  positive  for  IL-2  receptor, 
detectable  by mAb AT-1.  TPA  alone  also  induced  a  significant  number  of T 
cells to express IL-2 receptors.  However, the staining intensity of IL-2 receptor 
on  TPA-treated  T  cells  was  much  weaker  than  that  on  mAb  9.3  plus  TPA- 
treated T  cells (Fig. 4). 
IL-2 production  by mAb 9.3 and TPA-treated T  cells was examined with an 
IL-2-dependent murine T  cell line, HT-2. As shown in Table V, T  ceils treated 
with either mAb 9.3 or TPA alone did not secrete IL-2. A  considerable amount 
of IL-2  was  secreted  by  T  cells  treated  with  mAb  9.3  and  TPA.  Significant 
proliferation was seen even when culture supernatants were diluted  1:60.  As an 
added  control,  the  addition  of mAb 9.3  to  the  supernatant  of TPA-treated  T 
cells did not support the proliferation of HT-2 cell line. 
T3 Modulation Did Not Sign~cantly Affect  T  Cell Activation  with mAb 9.3 Plus 
TPA.  The  modulation  of the T3  complex in  9.3  mAb-induced  T  cells prolif- 
erating  in  the  presence  of TPA  was  studied.  Monocyte-depleted  T  cells  were 
treated  with  mAb  235  (an  IgM  anti-T3)  for  15  h  to  induce  T3  complex 
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FIGURE 3.  Time course of expression of IL-2 receptors  on T  cells. Monocyte-depleted T 
cells (2 x  105) were incubated in the presence ofmAb 9.3 (1 #g/ml) with or without TPA (0.6 
ng/ml). The percentages of IL-2 receptor-positive cells were determined by biotinylated AT- 
1 and FITC-avidin at the indicated times. 9.3 plus TPA (I), TPA alone (A), 9.3 alone (I-]), 
medium (O). 10,000 cells were analyzed with a Coulter  Epics V flow cytometer, as described 
in Materials and Methods. [SH]Thymidine incorporation  (cpm) was as follows: medium (313), 
9.3 antibody (173), TPA (1,306), 9.3 plus TPA (38,081). 1520  ACTIVATION  OF  HUMAN  T  CELLS  BY  MONOCLONAL  ANTIBODY  9.3 
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FIGURE  4.  Flow-cytometric  analysis of the expression of IL-2 receptors on T cells. Monocyte- 
depleted T cells were incubated with medium, mAb 9.3 (1 tzg/ml) alone (2), TPA (0.6 ng/ml) 
alone (3), and TPA plus mAb 9.3 (4).  IL-2 receptor-positive cells were analyzed with'a flow 
cytometer as described in Fig. 3.  (I) indicates the staining with nonbiotinylated AT-I and 
avidin-FITC. 
TABLE  V 
IL-2 Production by T Cells Treated with Antibody 9.3 With or 
Without TPA 
Treatment 
[SH]Thymidine incorporation at various 
dilutions of culture supernatant 
1:2  1:6  1:20  1:60 
cpm 
Medium  1,170  1,007  988  1,073 
mAb 9.3 (1 tzg/ml)  1,252  1,001  931  1,114 
TPA (0.6 ng/ml)  1,149  1,003  977  881 
TPA + mAb 9.3  6,026  5,077  3,891  2,559 
Monocyte-depleted T  cells (106/ml)  were incubated in the presence of 
mAb 9.3 (1 gg/ml) with or without TPA (0.6 ng/ml). After 12 h incuba- 
tion, supernatants were collected and assayed using an IL-2-dependent 
murine cell line (HT-2),  as described in  Materials and  Methods.  The 
standard deviations of each value were within 15 %. 
modulation,  mAb  235  modulates  T3  complex  on  T  cells  in  the  absence  of 
monocytes (our unpublished  observations). 
After  this  treatment,  2-5%  of residual T  cells remained  weakly positive for 
T3  antigen, as detected by immunofluorescence.  These T  cells were cultured in 
the presence of either anti-T3 or mAb  9.3 with TPA  to determine  the effect of 
T3  modulation. Anti-T3  plus TPA-induced  proliferation of T3-modulated  cells 
was  9  and  28%  of that  of nonmodulated  cells  on  days  2  and  3,  respectively 
(Table VI). On  the other  hand,  proliferation induced by mAb  9.3  plus TPA  in 
T3-modulated  cells was 92 and 85% of that of nonmodulated  cells on days 2 and HARA  ET  AL.  1521 
TABLE  VI 
Effect ofT3 Modulation on T Cell Proliferation Induced by mAb 9.3 
Plus TPA 
Day  Antibody for modula- 
tion 
[SH]Thymidine uptake when stim- 
ulated with TPA and: 
Anti-T3  mAb 9.3  Medium  (235) (1 
#g/ml)  (1 /zg/ml) 
Epm 
Medium  1,342  46,234  53,773 
Anti-T3 (235)  1,324  4,247  49,443 
Anti-Leu-1 (10.2)  1,450  43,327  55,267 
Medium  1,563  75,699  74,362 
Anti-T3 (235)  4,273  21,405  63,290 
Anti-Leu-1 (10.2)  1,473  72,177  74,540 
Monocyte-depleted T  cells (10  B cells/ml) were modulated with medium, 
anti-T3  mAb (235),  or anti-Leu-1  (10.2)  at  37°C for  15  h.  Cells were 
washed three times with media and further incubated with medium, anti- 
T3 (1  ~tg/ml),  or mAb 9.3 (1  ttg/ml) in the presence of 0.6 ng/ml TPA 
for 2 or 3 d. [SH]Thymidine incorporation was determined after an 8-h 
pulse. The standard deviations of each mean value were within 15%. 
3, respectively. Leu-1  modulation did not influence greatly T  cell proliferation, 
either with anti-T3 mAb plus TPA, or with mAb 9.3 plus TPA. 
Discussion 
The T3/Ti complex and the T 11 molecule have been shown (3, 5) to mediate 
two  T  cell  activation  pathways.  The  T3/Ti  pathway  is  antigen  specific  and 
dependent  on  the  presence  of monocytes.  The  T11  pathway  is  non-antigen 
specific  and  independent  of monocytes.  Despite  these  differences,  these  two 
pathways are related. The T 11 pathway is blocked by the modulation of the T3 
complex.  In  this  study,  a  third  T  cell activation  pathway  has  been  identified. 
This  pathway  is  mediated  by a  disulfide-bonded  dimer  of a  44  kD  structure 
identified  by mAb  9.3.  This  bimolecular  structure  is  similar  to that  of T  cell 
receptor  molecule,  Ti.  However, comodulation  experiments  with  anti-Ti  and 
anti-T3 antibodies, using HPB-ALL cells, showed that the Ti and 9.3 molecules 
are  not  the  same.  In  addition,  V8 protease  digestion  of Ti  and  9.3  antigens 
precipitated  from  z25I-surface-iodinated  HPB-ALL  cells  revealed  no  similar 
peptides.  Furthermore,  T  cell activation by mAb 9.3,  in the presence of TPA, 
was not affected  by T3  modulation.  These  results  suggest  that  9.3  activation 
pathway is different from those via T3 and T11. 
This  study and  our investigation  involving anti-T3  antibodies  (7) show that 
TPA  can  deliver  one  of  the  two  signals  needed  for  T  cell  activation  and 
proliferation. Anti-T3 antibodies or mAb 9.3 can deliver the other signal. These 
antibodies, in collaboration with TPA, can induce IL-2 receptor expression and 
IL-2 secretion by T  cells. These events precede T  cell proliferation in a manner 
similar to antigen-induced T  cell proliferation (1). Despite the similarity between 
the T3/Ti  pathway and  the 9.3 pathway, note that the T3/Ti  complex can be 1522  ACTIVATION  OF  HUMAN T  CELLS BY  MONOCLONAL ANTIBODY 9.3 
readily  and  completely  modulated,  while  antigen  9.3  can  only  be  partially 
modulated. The role of modulation of activation antigens in T  cells needs to be 
determined more clearly. 
mAb 9.3 was first reported in 1980 (15). In subsequent studies (17-21), it was 
established that this antibody identifies a  major subpopulation of T  cells. This 
population included T4 + helper/inducer T  cells, and T8 + cytotoxic T  cells. T8 ÷ 
suppressor T  cells do not react with mAb 9.3. Showing that mAb 9.3 is important 
in  the  mediation  of T  cell  proliferation  indicates  that  certain  structures  in  a 
subpopulation of T  cells are important in the activation process. Thus, multiple 
structures  are  involved  in  T  cell  activation.  This  is  supported  by  the  recent 
findings  that  several  mAb  against  different antigens  on  murine  T  cells  can 
augment or induce cloned T  cell proliferation (22,  23).  It is also possible that 
different structures are used by functionally distinct T  cell populations. Relevant 
to this discussion is the recent finding by Bensussan et al. (24) that cloned T8 + 
suppressor T  cells did not proliferate as a  result of T3/Ti  triggering. It would 
be of considerable interest to identify a  molecule on this 9.3-  population that 
would  mediate activation  and  proliferation  of these  T  cells.  Relevant to  this 
discussion is the preliminary finding that 9.3-  T  cells did not respond well to 
mitogens and anti-T3  mAb  in  the presence  of TPA.  These data suggest that 
activation mechanisms differ in different T  cell subsets. 
Our  preliminary experiments  indicate  that  mAb  9.3  augments anti-T3-in- 
duced T  cell proliferation in  the presence  of TPA.  This adds  support  to  the 
thesis that the T3/Ti and 9.3 activation pathways are independent.  Related to 
this point is the recent finding  2 that mAb 9.3 can augment suboptimal doses of 
anti-T3 and various T  cell mitogens to induce T  cell proliferation. These results 
also underline the need to ascertain the relative importance of these activation 
pathways in normal T  cell proliferation. 
Summary 
In previous studies (17-21),  monocional antibody (mAb) 9.3 has been shown 
to react with a  major population of human T  cells, which include T4 + helper/ 
inducer T  cells and T8 ÷ cytotoxic T  ceils.  In this investigation, mAb 9.3  was 
shown to precipitate a  disulfide-bonded dimer of a  44  kD polypeptide. Como- 
dulation experiments showed that this molecule is not linked to T3/Ti or T11 
antigens, mAb 9.3  was capable of inducing T  cell proliferation in the presence 
of 12-0-tetradecanoyl  phorbol-13-acetate  (TPA).  This effect was  monocyte-in- 
dependent. T  cell activation with mAb 9.3 and TPA was associated with increases 
in interleukin 2 (IL-2) receptor expression and IL-2 secretion, mAb 9.3 did not 
activate T  cells, even with the addition of IL-1  or IL-2.  Modulation of the T3 
complex did not abolish mAb 9.3-induced T  cell proliferation in the presence 
of TPA. These results suggest that the 9.3 antigen may serve as a  receptor for 
an activation pathway restricted to a T  cell subset. 
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